Premium
Therapeutic effects of fengabine, a new GABAergic agent, in depressed outpatients: a double‐blind study versus clomipramine
Author(s) -
Nielsen N. P.,
Cesana B.,
Zizolfi S.,
Ascalone V.,
Priore P.,
Morselli P. L.
Publication year - 1990
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1990.tb01402.x
Subject(s) - clomipramine , anticholinergic , sedative , medicine , double blind , gabaergic , psychology , drug , anesthesia , psychiatry , alternative medicine , receptor , pathology , placebo
The results of a double‐blind clinical trial of fengabine vs clomipramine in depressed outpatients are reported. Fengabine, a new GABAergic agent, seems to be as effective as the reference drug, with a faster onset of action and a more marked effect on cognitive disturbances and retardation. The new drug is free of any significant anticholinergic or cardiovascular effect, and it is not sedative.